Plain-English translation of NCT04787848 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are studying chronic widespread pain in people with HIV to understand why it happens and find better treatments. This trial uses a medication called methylnaltrexone bromide (RELISTOR) to help explore how the body's natural pain-fighting systems work differently in people with HIV. The study compares pain responses in four groups: people with HIV with and without chronic pain, and people without HIV with and without chronic pain.
People with HIV experience chronic widespread pain 10 times more often than others, leading to severe disability and overuse of opioid medications. Currently, doctors don't fully understand why this happens, so this medication is being used as a research tool to help identify the root cause and develop better, safer pain treatments.
You likely qualify if…
You likely don't qualify if…
You would attend two study visits where you receive pain sensitivity testing (called quantitative sensory testing) before and after receiving either the study medication or a placebo injection. The medication is given based on your body weight, and researchers measure how your body responds to mild pain stimuli like cold or pressure. Your participation helps scientists understand the biological reasons behind HIV-related chronic pain so better treatments can be developed.
AI-generated summary from trial data · Aug 7, 2026 · Not medical advice
United States
Sponsor
Florida International University
Enrollment target
~200 participants
Started
November 2021
Primary completion
May 2027
Age range
19 Years – 65 Years
Last updated on clinicaltrials.gov in September 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Saurabh Aggarwal, MD., PhD
Florida International University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.